Eloralintide
LY3841136 · Eli Lilly
Selective amylin agonist tested as monotherapy and adjunctive treatment.
Selected study results
48-week dose-finding trialMean body-weight reductionBody weight decreased 20% · 48 weeks · Phase 2
Mean body-weight reduction · 48 weeks
Study focus: Weight management without type 2 diabetes
Adults with obesity or overweight and a weight-related complication, without diabetes · 9 mg once weekly vs placebo · Trial N=263 · Efficacy estimand; rounded values in published abstract. Results & methods ↗
Nausea and fatigue were common and varied by dose and escalation schedule. Phase 3 confirmation remains important.
Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.
Mechanism at a glance
Obesity stage by formulation
Latest: Phase 3 includes weight management, obstructive sleep apnea, and knee osteoarthritis programs; the published Phase 2 dose-finding study remains evidence context.
Next: Phase 3 ENLIGHTEN weight-management and related-condition outcomes.
Clinical study records
Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.
Obesity and weight-management studies
Phase 3 studies5 records
ENLIGHTEN-1
Weight managementAdults with obesity or overweight without type 2 diabetes; chronic weight management.
ENLIGHTEN-10
Weight and glycemic control at high cardiovascular riskRegistered Phase 3 in an estimated 3,000 adults with obesity or overweight, type 2 diabetes and increased cardiovascular risk; weight at week 64 and HbA1c at week 36 are primary endpoints. This is not a cardiovascular-events outcomes trial. Not yet recruiting.
ENLIGHTEN-2
Weight management with type 2 diabetesAdults with obesity or overweight and type 2 diabetes; weight-management outcomes.
ENLIGHTEN-4
Weight management with knee osteoarthritisAdults with obesity or overweight and painful knee osteoarthritis; assesses weight and osteoarthritis outcomes.
ENLIGHTEN-6
Add-on weight managementAdults with persistent obesity or overweight despite stable weekly incretin-based therapy; includes participants with or without type 2 diabetes.
Phase 2 studies1 record
Eloralintide dose-finding study
Weight managementCompleted 48-week dose-ranging study in adults with obesity or overweight and a weight-related complication, without type 2 diabetes; published.
Related conditions and outcomes
Phase 3 studies1 record
ENLIGHTEN-3
Sleep-apnea outcomesAdults with obesity and moderate-to-severe obstructive sleep apnea; master protocol includes separate PAP-use substudies.
